TFRC and neoplasm: Anti-transferrin receptor antibody-ricin and transferrin-ricin immunotoxins have been tested in a variety of cancer settings where their cytotoxic activity was demonstrated to be highly potent, tumor cell type-specific and correlated with the expression of the transferrin receptor [63,64].